Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type

Luca Schifanella, Susan W Barnett, Massimiliano Bissa, Veronica Galli, Melvin N Doster, Monica Vaccari, Georgia D Tomaras, Xiaoying Shen, Sanjay Phogat, Ranajit Pal, David C Montefiori, Celia C LaBranche, Mangala Rao, Hung V Trinh, Robyn Washington-Parks, Namal P M Liyanage, Giacomo Gorini, Dallas R Brown, Frank Liang, Karin LoréDavid J Venzon, William Magnanelli, Michelle Metrinko, Josh Kramer, Matthew Breed, Galit Alter, Ruth M Ruprecht, Genoveffa Franchini

Research output: Contribution to journalArticle

Abstract

[This corrects the article DOI: 10.1371/journal.ppat.1008121.].

Original languageEnglish (US)
Pages (from-to)e1008531
JournalPLoS pathogens
Volume16
Issue number4
DOIs
StatePublished - Apr 2020

PubMed: MeSH publication types

  • Journal Article
  • Published Erratum

Fingerprint Dive into the research topics of 'Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type'. Together they form a unique fingerprint.

  • Cite this

    Schifanella, L., Barnett, S. W., Bissa, M., Galli, V., Doster, M. N., Vaccari, M., Tomaras, G. D., Shen, X., Phogat, S., Pal, R., Montefiori, D. C., LaBranche, C. C., Rao, M., Trinh, H. V., Washington-Parks, R., Liyanage, N. P. M., Gorini, G., Brown, D. R., Liang, F., ... Franchini, G. (2020). Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. PLoS pathogens, 16(4), e1008531. https://doi.org/10.1371/journal.ppat.1008531